Another bidder (BDR) revisits

Research output: Contribution to journalComment/debatepeer-review

7 Scopus citations


In this issue of Blood, Gavriatopoulou and colleagues report the mature results of the European Myeloma Network (EMN)-conducted phase 2 trial evaluating the activity of bortezomib, dexamethasone, and rituximab (BDR) in treatment-naïve patients with Waldenström macroglobulinemia (WM).1 An array of combination regimens has been studied in WM, and the ever-growing list of bidders contributes to the conundrum of choosing an appropriate regimen.2

Original languageEnglish (US)
Pages (from-to)398-400
Number of pages3
Issue number4
StatePublished - Jan 26 2017

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Another bidder (BDR) revisits'. Together they form a unique fingerprint.

Cite this